Active ingredient Alprostadil interacts in the following cases:

Antihypertensives, vasodilative agents, anticoagulants, platelet aggregation inhibitors

Alprostadil may enhance the effects of antihypertensives, vasodilative agents, anticoagulants and platelet aggregation inhibitors.


Sympathomimetics may reduce the effect of alprostadil.

Transient ischaemic attacks, unstable cardiovascular disorders

Alprostadil should be used with caution in patients who have experienced transient ischaemic attacks or those with unstable cardiovascular disorders.


Urethral stick may add small amounts of alprostadil to the naturally occurring PGE1 already present in the semen. A condom barrier should therefore be used during sexual intercourse if the female partner is pregnant to avoid irritation of the vagina and guard against any risk to the foetus.

Nursing Mothers

Not applicable.

Carcinogenesis, Mutagenesis and Fertility


High doses of alprostadil (0.5 to 2.0 mg/kg subcutaneously) had an adverse effect on the reproductive potential of male rats, although this was not seen with lower doses (0.05 to 0.2 mg/kg). Alprostadil did not affect rat spermatogenesis at doses 200 times greater than the proposed human intrapenile dose.

Effects on Ability to Drive and Use Machines

Patients should be cautioned to avoid activities, such as driving or hazardous tasks, where injury could result if hypotension or syncope were to occur after alprostadil administration. In patients experiencing hypotension and/or syncope, these events have usually occurred during initial titration and within one hour of drug administration.